Sarepta Therapeutics, Inc.
SRPT
$105.56
-$2.11-1.96%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 40.94% | 28.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 40.94% | 28.72% | |||
| Cost of Revenue | 5.09% | 41.00% | |||
| Gross Profit | 116.00% | 8.87% | |||
| SG&A Expenses | 27.83% | -7.63% | |||
| Depreciation & Amortization | -0.17% | 0.17% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.63% | 22.37% | |||
| Operating Income | 628.42% | 3,266.33% | |||
| Income Before Tax | 405.04% | 150.47% | |||
| Income Tax Expenses | 3,113.67% | -94.45% | |||
| Earnings from Continuing Operations | 373.21% | 420.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 373.21% | 420.29% | |||
| EBIT | 628.42% | 3,266.33% | |||
| EBITDA | 437.89% | 299.13% | |||
| EPS Basic | 368.76% | 415.96% | |||
| Normalized Basic EPS | 649.05% | 665.05% | |||
| EPS Diluted | 375.97% | 395.90% | |||
| Normalized Diluted EPS | 599.78% | 663.84% | |||
| Average Basic Shares Outstanding | 0.94% | 0.82% | |||
| Average Diluted Shares Outstanding | 7.99% | 1.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
